FFF

FUSION ANTIBODIES PLC ORD GBP0.04

No trades
See on Supercharts
Market capitalization
‪3.62 M‬GBP
−0.09GBP
‪−2.60 M‬GBP
‪2.90 M‬GBP
‪79.84 M‬
Beta (1Y)
−0.94

About FUSION ANTIBODIES PLC ORD GBP0.04

CEO
Adrian Kinkaid
Headquarters
Belfast
Founded
2000
ISIN
GB00BDQZGK16
FIGI
BBG00JDYBTZ5
Fusion Antibodies Plc engages in research, development, and manufacturing recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The firm also offers antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company was founded by Michael Townsley and James Anthony Johnston on November 29, 2000 and is headquartered in Belfast, the United Kingdom.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of FAB is 3.50 GBX — it has decreased by 6.64% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange FUSION ANTIBODIES PLC ORD GBP0.04 stocks are traded under the ticker FAB.
FUSION ANTIBODIES PLC ORD GBP0.04 is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
FAB stock is 7.11% volatile and has beta coefficient of −0.94. Check out the list of the most volatile stocks — is FUSION ANTIBODIES PLC ORD GBP0.04 there?
Yes, you can track FUSION ANTIBODIES PLC ORD GBP0.04 financials in yearly and quarterly reports right on TradingView.
FAB stock has fallen by 5.89% compared to the previous week, the month change is a 12.48% fall, over the last year FUSION ANTIBODIES PLC ORD GBP0.04 has showed a 89.41% decrease.
FAB net income for the last quarter is ‪−1.36 M‬ GBP, while the quarter before that showed ‪−1.48 M‬ GBP of net income which accounts for 8.31% change. Track more FUSION ANTIBODIES PLC ORD GBP0.04 financial stats to get the full picture.
No, FAB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, FAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FUSION ANTIBODIES PLC ORD GBP0.04 stock right from TradingView charts — choose your broker and connect to your account.
FAB reached its all-time high on Sep 18, 2020 with the price of 250.00 GBX, and its all-time low was 3.02 GBX and was reached on Nov 24, 2023.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So FUSION ANTIBODIES PLC ORD GBP0.04 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating FUSION ANTIBODIES PLC ORD GBP0.04 stock shows the sell signal. See more of FUSION ANTIBODIES PLC ORD GBP0.04 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. FUSION ANTIBODIES PLC ORD GBP0.04 EBITDA is ‪−2.78 M‬ GBP, and current EBITDA margin is −84.83%. See more stats in FUSION ANTIBODIES PLC ORD GBP0.04 financial statements.